ライフサイエンスコーパス: leukocyte count

1 cal inflammation (elevated polymorphonuclear leukocyte count).

2 natriuretic peptide, C-reactive protein, and leukocyte count.

3 ex, histology, probability of diagnosis, and leukocyte count.

4 rs of fibrinogen, log C-reactive protein, or leukocyte count.

5 ed with low steady-state hemoglobin and high leukocyte count.

6 logy Group 8602, matched on age, gender, and leukocyte count.

7 tment regimen, risk classification, age, and leukocyte count.

8 ase of the G-CSF successfully normalized his leukocyte count.

9 The high-iron diet alone increased leukocyte count.

10 rse outcomes, with the possible exception of leukocyte count.

11 ease is unassociated with a reduction in the leukocyte count.

12 was quantified 6 hours later by pouch fluid leukocyte counts.

13 , an adverse event associated with increased leukocyte counts.

14 Vehicle challenge did not increase leukocyte counts.

15 ociated with loss of organ function and high leukocyte counts.

16 ences observed between the mean differential leukocyte counts.

17 erican participants had slightly higher mean leukocyte counts (0.16 x 10(9) cells/L; P = 0.014), high

18 (4.2 +/- 0.3 log(10) DNA copies/ml) and high leukocyte counts (143 +/- 62 cells/microl); and patients

19 f 4.8 +/- 0.2 log(10) DNA copies/ml) and low leukocyte counts (22 +/- 7 cells/microl); encephalitis w

20 3.0 +/- 0.2 log(10) DNA copies/ml) with high leukocyte counts (88 +/- 57 cells/microl).

21 This resulted in a 10-fold increase in leukocyte count, a 3-fold increase in platelets, and mob

22 ears or older (P = .005), those with initial leukocyte count above 50 x 10(9)/L (P = .03), and those

23 Leukocytosis refers to an increase in leukocyte count above the normal range in the blood and

24 haracteristics of the child (age), leukemia (leukocyte count, acquired genetic characteristics) and e

25 In multivariable analysis, a higher leukocyte count (adjusted odds ratios [aOR] 1.10; 95% CI

26 or necrosis factor-alpha, interleukin-6, and leukocyte counts (all p < 0.001).

27 The exudate leukocyte count and adenosine concentration were determi

28 A high leukocyte count and an elevation in inflammatory markers

29 l logistic regression confirmed that initial leukocyte count and antibiotic use were independently as

30 Leukocyte count and CD64 expression on neutrophils (nCD6

31 ogic evidence for a relationship between the leukocyte count and coronary heart disease (CHD).

32 ue, the author examined the relation between leukocyte count and erythrocyte sedimentation rate and d

33 Different timing of measurements of leukocyte count and serum creatinine level around the CD

34 m, which predicted cerebrospinal fluid (CSF) leukocyte count and survival of Vietnamese patients with

35 o, we assigned 2 points to age and 1 each to leukocyte count and thrombosis.

36 Elevations of the hepatic transaminases and leukocyte counts and a decline in hematocrit count were

37 an-treated animals showed increases in total leukocyte counts and enhanced bacterial clearance from b

38 dynamics of alteration in polymorphonuclear leukocyte counts and expression of CD11b adhesion molecu

39 Blood was drawn for leukocyte counts and liver function tests.

40 oalveolar lavage fluid, ii) lung parenchymal leukocyte counts and lymphoid aggregates, iii) lung oxid

41 d IL-6, the chemokines MIP-1alpha and MIP-2, leukocyte counts and myeloperoxidase activity (neutrophi

42 studies, we have used PoC biochip to monitor leukocyte counts and nCD64 levels from patients' blood a

43 ressure, lower ultrafiltration rates, higher leukocyte counts and neutrophil-to-lymphocyte ratios.

44 Leukocyte counts and plasma neopterin levels were determ

45 sm had significant increases in platelet and leukocyte counts and reduction in spleen size.

46 Elevations of leukocyte counts and TNF levels in bronchoalveolar fluid

47 ic oxide synthase expression), inflammation (leukocyte count), and angiogenesis (CD31 expression) wer

48 nt age, constitutional symptoms, hemoglobin, leukocyte count, and circulating blasts.

49 e Sequential Organ Failure Assessment score, leukocyte count, and endothelium-dependent vasodilatatio

50 B-precursor leukemia, including age, initial leukocyte count, and hyperdiploidy.

51 After adjusting for age, performance status, leukocyte count, and karyotype in a proportional hazards

52 terized by higher numbers of organ failures, leukocyte count, and mortality compared with ACLF in pat

53 ne C-reactive protein (CRP), fibrinogen, and leukocyte count, and recorded admissions due to ischemic

54 the intranasal route, and bacterial burdens, leukocyte counts, and cytokine levels were determined.

55 We reviewed the histology, leukocyte counts, and PCR data for inflammatory genes, t

56 yed-type hypersensitivity responses, lowered leukocyte counts, and reduced lymphocyte proliferation a

57 lky disease, lower hemoglobin levels, higher leukocyte counts, and similar diffuse uptake in the sple

58 usly elevated levels of CRP, fibrinogen, and leukocyte count are associated with a two- to fourfold i

59 these mice, even at ambient air, peripheral leukocyte counts are elevated by 1.7-fold and neutrophil

60 more specific assay is warranted or in which leukocyte counts are inadequate to perform cell-based as

61 FLT3/ITD-positive patients had higher median leukocyte count at diagnosis (59 v 21 x 10(9)/L; P < .00

62 multivariable analysis, risk group (age and leukocyte count at diagnosis) and asparaginase treatment

63 ostic significance after adjustment for age, leukocyte count at diagnosis, and genetic subtype.

64 mg/m2 > 100 mg/m2; P=0.00001), logarithm of leukocyte count at the time of diagnosis (P=0.0005), and

65 did not differ in gender, immune phenotype, leukocyte count at the time of diagnosis, chromosome abn

66 ther the level of C-reactive protein nor the leukocyte count at the time of PET/MRI was related to th

67 used significant increases from prechallenge leukocyte counts at 10 min (p<0.03), 30 min (p<0.01), an

68 Further adjustment for weight change and leukocyte count attenuated these risks substantially.

69 Both platelet and leukocyte counts became normal in splenic patients, wher

70 Cerebrospinal fluid leukocyte counts began to decrease by day 13 of treatmen

71 there were no differences in BAL fluid total leukocyte counts between resistant and susceptible subje

72 glycerides, cholesterol, C-reactive protein, leukocyte count, blood pressure, and Framingham risk sco

73 , fibrinogen levels, chronic kidney disease, leukocyte count, C-reactive protein levels, homocysteine

74 is of favorable age and has a low presenting leukocyte count, can be cured with chemotherapy alone.

75 CSF leukocyte counts, CD4(+) and CD8(+) T cells, CD19(+) B c

76 gher platelet count and lower hemoglobin and leukocyte count compared with JAK2- and MPL-mutated pati

77 effects (percentage decrease in circulating leukocyte counts) compared with MP alone (-50% +/- 4%, -

78 n 1 hr of lipopolysaccharide infusion, total leukocyte counts decline.

79 human heart transplant recipients the total leukocyte count decreased prior to the time of diagnosis

80 e measurements presented significantly lower leukocyte counts determined by the MIC.

81 ts displayed significantly higher peripheral leukocyte counts, early depletion of common lymphoid pro

82 Multivariate analysis confirmed leukocyte count, Eastern Cooperative Oncology Group perf

83 Treatment with 901 induced a durable drop in leukocyte counts, enhanced erythropoietic function, and

84 sma cytokines levels, total and differential leukocyte counts, expression of leukocyte cell surface r

85 ty C-reactive protein, ankle-brachial index, leukocyte count, fasting blood glucose, periodontal dise

86 y, lipoprotein(a) level, homocysteine level, leukocyte count, fasting blood glucose, periodontal dise

87 The median baseline leukocyte count for patients with leukocytosis was 3,900

88 No significant differences in age, sex, leukocyte count, French-American-British subtype, or kar

89 reported fever (OR, 8.3 [CI, 1.6 to 50.0]), leukocyte count greater than 10 x 10(9)/L (OR, 4.0 [CI,

90 ome (P <.001), and no patient without a peak leukocyte count greater than 10,000 cells/microL develop

91 sk prognostic features, including an initial leukocyte count greater than 100 x 10(3)/ microL, a T-ce

92 e prophylaxis and exclusion of patients with leukocyte counts greater than 200x10(9)/L have made this

93 its; hematopoietic, platelet count > 50 K or leukocyte count > 4.5 K, mortality, and costs.

94 (CRP > 3 mg/L, fibrinogen > 14 mumol/L, and leukocyte count > 9 x 10(9)/L) versus individuals with a

95 temperature > or = 100.5 and a preoperative leukocyte count > or = 10,000 were incapable of discrimi

96 onclusion, IPSET, based on age >/= 60 years, leukocyte count >/= 11 x 10(9)/L, and history of thrombo

97 Age 60 years or older, leukocyte count >/= 11 x 10(9)/L, and prior thrombosis s

98 ciated with age less than 1 year (P < .001), leukocyte count >50 x 10(9)/L (P = .003), and the absenc

99 r modality should be retained for cases with leukocyte counts > 100 x 10(9)/L.

100 ation >12 mmol/L, Na(+) : K(+) >1, and total leukocyte counts > or =10(6) cells/mL, respectively.

101 .6), to cough >/=14 days (aOR, 6.3), to have leukocyte counts >20 000 cells/microL (aOR, 4.6), and to

102 male sex, the absence of surgical resection, leukocyte counts >6.0 x 10(9)/L, and levels of hemoglobi

103 body temperature>38 or <36 degrees C, or 4) leukocyte count>12 or<4x10/L.

104 ollowed by measuring body weight, peripheral leukocyte counts, GVHD, survival, and cytokine response.

105 or event-free survival identified older age, leukocyte count higher than 30 x 10(9)/L, presence of Ph

106 association between house dust endotoxin and leukocyte count in a national survey.

107 MTX significantly reduced the exudate leukocyte count in C57BL/6J and BALB/cJ mice, but not DB

108 Apart from a significantly higher leukocyte count in E. histolytica-positive patients than

109 ly elevated levels of CRP and fibrinogen and leukocyte count in individuals with COPD were associated

110 mice with i.p. bilirubin decreases the total leukocyte count in the lung parenchyma and lavage fluid,

111 CSF examination at 3 months showed decreased leukocyte counts in all patients; however, 23.3% still h

112 Although no differences in total leukocyte counts in chamber fluids were observed between

113 dust endotoxin concentration and peripheral leukocyte counts in human subjects.

114 Differential leukocyte counts in the normal clinical range from finge

115 GF-beta1 were thus correlated with the total leukocyte counts in the synovial fluids.

116 Polymorphonuclear leukocyte counts increased through the following 3- and

117 The peripheral leukocyte count is a biomarker of inflammation and is as

118 The leukocyte count is a marker of inflammation that is wide

119 The leukocyte count is inexpensive, reliable, easy to interp

120 cating a favorable prognosis were presenting leukocyte count less than 50 x 10(9)/L (relative risk of

121 both AL patients (P = .01) and patients with leukocyte counts less than 100/mm(3) (P = .001).

122 igh-risk features, including older age, high leukocyte count, leukemia with a T-cell phenotype, the P

123 analysis, adjusting for sex, age, presenting leukocyte count, leukemic cell DNA index, immunophenotyp

124 mice also had significantly lower pulmonary leukocyte counts, lower interleukin 1beta and interferon

125 mes were the occurrence of hematologic ADRs (leukocyte count < 3.0*10(9)/L or reduced platelet count

126 ex, middle age (age, 30-60 years), headache, leukocyte count <10 x 10(9)/L and C-reactive protein lev

127 Peripheral leukocyte count may be influenced by residential endotox

128 e participants, black participants had lower leukocyte counts (mean difference, 0.89 x 10(9) cells/L;

129 or use of erythropoiesis-stimulating agents, leukocyte count more than 11 x 10(9)/L, and body mass in

130 L patients (P = .0003), and in patients with leukocyte counts more than 100/mm(3) (P = .002).

131 dence interval, 1.33-36.5) for patients with leukocyte counts more than 100/mm(3).

132 mite-treated Adam8(-/-) mice had higher lung leukocyte counts, more airway mucus metaplasia, greater

133 Polymorphonuclear leukocyte counts, murine GRO-alpha (KC), and macrophage

134 Total leukocyte counts, myeloperoxidase, nitric oxide producti

135 Blood glucose level, total leukocyte count, neutrophil count, and leukocyte labelin

136 clinical factors, such as age and presenting leukocyte count, no longer identify the 20% of newly dia

137 Differential leukocyte counts obtained from fingerprick samples accur

138 proportional hazards for participants with a leukocyte count of > or = 9.1 x 10(9)/liter compared wit

139 0(9)/liter compared with participants with a leukocyte count of < or = 5.7 x 10(9)/liter were 1.33 (9

140 patients who had T-cell ALL and a presenting leukocyte count of 100 x 10(9)/L or more, or CNS-3 (5 or

141 ved in all patients; leukopenia (with median leukocyte count of 1400/mm3) was the most commonly effec

142 The leukocyte count of 213,000/cu mm, being among the highes

143 .1 g/dL (reference range, 13.8-17.5 g/dL), a leukocyte count of 8.1 x 10(9)/L (reference range, [3.4-

144 The patients had to have a leukocyte count of at least 3000 per cubic millimeter, a

145 Neither the leukocyte counts on day 0 nor those during the 6-day neu

146 use (AOR, 2.78; 95% CI, 1.04-7.48), and high leukocyte counts on vaginal smear (AOR, 1.18; 95% CI, 1.

147 lly significant reduction in erythrocyte and leukocyte counts; only the reduction in erythrocyte coun

148 There were no perturbations of the leukocyte count or differential noted.

149 ere assessed 2 days later for VEGF ELISA and leukocyte counting or 1 week later for quantification of

150 kin-6 concentration (p < 0.001) and alveolar leukocyte count (p = 0.03) and a minor increase in bronc

151 ses in symptoms, temperature (P=.016), total leukocyte count (P=.014), tumor necrosis factor-alpha (P

152 tion: (a) younger age (P < 0.008); (b) lower leukocyte count (P=0.01); (c) the presence of Auer rods

153 nths for platelet counts, hemoglobin levels, leukocyte counts (P < .001), and ET-related events (HR,

154 ors had higher D-dimer levels (P = .008) and leukocyte counts (P < .001), and lower hemoglobin levels

155 edimentation rate (ESR), C-reactive protein, leukocyte count, presence of antinuclear antibodies (ANA

156 us humor of the right eyes was collected for leukocyte count, protein concentration, and IL-6 assay.

157 This was confirmed by decreases in leukocyte count, protein concentration, and IL-6 level i

158 1.38 (1.19 to 1.59) for waist circumference, leukocyte count, serum albumin, and fibrinogen, respecti

159 Adjusting for age, leukocyte count, sex, era of treatment, and leukemia bla

160 tors such as age at diagnosis and presenting leukocyte count should be taken into consideration when

161 Balb/c mice demonstrating markedly elevated leukocyte counts, splenomegaly, and reticulin fibrosis c

162 stratified for age (subdivided at 10 years), leukocyte count (subdivided at 50,000), and gender, the

163 Third, the reduction in leukocyte count that occurs during CMV disease appears t

164 tive biomarkers include elevated platelet or leukocyte counts, tissue factor, soluble P-selectin, and

165 , 95% CI 1.12-1.18) adjusting for age, Total Leukocyte count (TLC) and pretreatment levels of ALT, ir

166 conjugates, or failure of the total absolute leukocyte count to accurately reflect the population use

167 Hemodynamic parameters, leukocyte counts, total left ventricular weight, and are

168 On the contrary, having no response in leukocyte count was associated with higher risk of death

169 response to RA treatment, an increase in the leukocyte count was noted.

170 Levels of CRP and fibrinogen and leukocyte count were defined as high or low according to

171 calcitonin, C-reactive protein, lactate, and leukocyte count were determined at admission and 12-24 h

172 C-reactive protein (CRP) and fibrinogen and leukocyte count were measured in participants at a time

173 Higher CLIF-SOFA scores and leukocyte counts were independent predictors of mortalit

174 On-treatment leukocyte counts were obtained every 2-6 weeks.

175 Total and differential leukocyte counts were performed on blood samples collect

176 Leukocyte counts were recorded during the first 4 days f

177 Monocyte and leukocyte counts were reduced, and the activation state

178 Baseline and peak leukocyte counts were similar between Mac-1(-/-) and WT,

179 Therefore, the patterns of changes in leukocyte counts were similar, with little evidence that

180 sodium : potassium ratio [Na(+) : K(+)], and leukocyte count) were related to breast milk HIV-1 RNA a

181 in haematopoietic ANGPTL4 have higher blood leukocyte counts, which is associated with an increase i

182 For leukocyte count, with 5337 CHD cases in the 7 largest st

183 n treatment also alters circadian rhythms of leukocyte counts within the lung in a bmal1-dependent ma

184 sis access, hemoglobin, serum albumin, blood leukocyte count, Wright/Khan index, and eC(Cr) at the st